INSTRUCTIONS Crohn disease: Recognition is key
* To take the test online, go to our secure website at http://www.nursingcenter.com/ce/NP.
* On the print form, record your answers in the test answer section of the CE enrollment form on page 29. Each question has only one correct answer. You may make copies of these forms.
* Complete the registration information and course evaluation. Mail the completed form and registration fee of $24.95 to: Lippincott Williams & Wilkins, CE Group, 74 Brick Blvd., Bldg. 4, Suite 206, Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form.
* You will receive your CE certificate of earned contact hours and an answer key to review your results.There is no minimum passing grade.
* Registration deadline is December 31, 2014.
DISCOUNTS and CUSTOMER SERVICE
* Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together and deduct $0.95 from the price of each test.
* We also offer CE accounts for hospitals and other healthcare facilities on nursingcenter.com. Call 1-800-787-8985 for details.
Lippincott Williams & Wilkins, publisher of The Nurse Practitioner journal, will award 2.5 contact hours for this continuing nursing education activity.
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.5 contact hours. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #FBN2454.
Your certificate is valid in all states. This activity has been assigned 1.5 pharmacology credits.
The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing educational activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.
Crohn disease: Recognition is key
General Purpose: To provide information on the diagnosis and management of CD. Learning Objectives: After reading the preceding article and taking this test, you should be able to: 1. Identify the epidemiology, signs and symptoms, and complications of and risk factors for CD. 2. Discuss the diagnosis and the treatment of patients with CD.
1. Which statement about CD is accurate?
a. CD occurs primarily in people ages 40 to 50 years old.
b. CD is an autoimmune disease.
c. No familial trend has been identified for CD.
d. CD is more common in the southern than in the northern part of the United States
2. There is a higher incidence of CD in
3. A factor that aggravates the course of CD is
b. a diet lacking saturated fat.
c. small, frequent meals.
d. active smoking.
4. Common symptoms of CD include
a. pain before meals.
b. weight gain.
c. rectal bleeding.
d. upper quadrant abdominal pain.
5. Typically, CD may cause all of the following except
b. fatty stools.
d. fistula formation.
6. Which of the following usually contributes the most to developing a working diagnosis of CD?
a. family history
b. pertinent clinical findings
c. history of recent infection
d. response to medication
7. A common physical finding in CD is
a. a positive McBurney sign.
b. hyperactive BS.
c. a positive psoas sign.
d. bilateral LQ abdominal pain.
8. A lab test that may be useful in differentiating CD from UC is
a. liver function tests.
b. a CBC.
c. protein biomarkers.
d. an ESR.
9. First-line testing for the initial workup of CD includes
a. a left lateral decubitus X-ray.
b. upper and lower GI series.
c. video capsule endoscopy.
10. Which test is used when a diagnosis of appendicitis needs to be rapidly ruled out?
d. flat and upright X-ray
11. Bowel loop narrowing that may occur in CD is known as
b. a positive string sign.
c. skip lesion.
12. Skip lesions are
a. noncontinuous bowel lesions found in CD.
b. precancerous lesions throughout the colon.
c. classic findings of H. pylori infection.
d. continuous disease involvement of the colon found in UC.
13. The use of probiotics has been shown to
a. control refractory diarrhea.
b. reduce intestinal normal flora.
c. inhibit prostaglandins.
d. increase host vitality.
14. Which drug suppresses T-cell activation?
15. Patients receiving azathioprine must receive education about
a. GI irritation and abdominal pain.
b. increased susceptibility to infection and communicable disease prevention.
c. dietary restrictions while taking the drug.
d. increased risk of bleeding.
16. Which drug category acts as antibodies to TNF?
a. 5-aminosalicylic acids
17. The authors suggest treating CD-associated arthritic joint pain with
a. nonsteroidal anti-inflammatory drugs.
18. Small areas of significant bowel narrowing are generally treated with a
c. bowel resection.